Please use this identifier to cite or link to this item:
|Title:||HuCNS-SC StemCells||Authors:||Taupin, P.||Issue Date:||Apr-2006||Citation:||Taupin, P. (2006-04). HuCNS-SC StemCells. Current Opinion in Molecular Therapeutics 8 (2) : 156-163. ScholarBank@NUS Repository.||Abstract:||HuCNS-SC, a proprietary human neural stem cells product, is being developed as a cellular therapy for the potential treatment of Batten disease, one of a group of disorders known as neural ceroid lipofuscinoses (NCL). Developer StemCells is also investigating the therapy for spinal cord injury and other central nervous system disorders, such as demyelinating disease, stroke and Alzheimer's disease. A phase I trial of HuCNS-SC for infantile and late-infantile NCL has been initiated, following the March 2006 US Food and Drug Administration approval of StemCells' investigational new drug application. © The Thomson Corporation.||Source Title:||Current Opinion in Molecular Therapeutics||URI:||http://scholarbank.nus.edu.sg/handle/10635/133071||ISSN:||14648431|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Apr 19, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.